Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.

You may also be interested in...



Financings Of The Fortnight Ponders A Post-Euro Financing Environment

Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.

Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line

In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.

Disappointing Provenge Sales Stir Doubts About Demand

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS073005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel